Toolong, you’ve touched on a core value driver. Bavi will compliment and supercharge a number of SOC drugs in treating the many solid tumor cancers and in a number of viral diseases; starting with HCV. We know bavi works synergistically, allowing other drugs to perform markedly beyond their initial approval data.
Bavi is just the first mAb in Peregrines powerful anti-PS platform which employs the body’s own powerful immune system to fight disease. The human data is coming in. Bavi is performing superbly after a number of human trials and showing a really good safety profile, as well. I’m confident, with continuity; it will be a multi-billion dollar drug in a platform among further platforms like anti-PE and (TNT); Cotara.
The trials are progressing, and I fully expect a cash-fluent pharma will, soon enough, feel compelled to close with Peregrine, pretty much on her terms, for this wide array of medical technologies.
What will those terms be? Who? When?
sunstar
News 
Market Data 
Discover 
